- Home
- BRW vs CLLS Comparison
BRW vs CLLS Comparison
Compare BRW & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.6M | 374.2M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRW | CLLS |
|---|---|---|
| Price | $6.53 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 273.4K | 30.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.38 | $1.10 |
| 52 Week High | $8.49 | $5.48 |
Technical Indicators
Market Signals| Indicator | BRW | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 42.55 |
| Support Level | N/A | $3.41 |
| Resistance Level | $7.10 | $3.77 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 46.60 | 15.58 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.